A recent study revealed how the chikungunya virus continues to cause joint pain for months to years after the initial infection.
According to a study published in the journal PLOS Pathogens by Deborah Lenschow of Washington University School of Medicine in St. Louis, and colleagues, the long-term disease could aid in the development of treatments and preventative measures for incapacitating virally induced chronic arthritis.
Chikungunya virus is spread by mosquitoes and causes severe joint and muscle pain. Approximately 30 to 60 per cent of people infected with the virus continues to experience joint pain for months to years after the initial infection.
However, the cause of this persistent joint pain is unclear, as a replicating virus cannot be detected during the chronic phase. To address this question, Lenschow and colleagues developed a reporter system to permanently mark cells infected by chikungunya virus.
Using this system, they show in mice that marked cells surviving chikungunya virus infection are a mixture of muscle and skin cells that are present for at least 112 days after initial virus inoculation.
Treatment of mice with an antibody that blocks chikungunya virus infection reduces the number of marked cells in the muscle and skin. Moreover, surviving marked cells contain most of the persistent chikungunya virus RNA.
Taken together, the findings provided further evidence for musculoskeletal cells as targets of chikungunya virus infection in the acute and chronic stages of the disease.
According to the authors, this reporter system represented a useful tool for identifying and isolating cells that harbor chronic viral RNA in order to study the mechanisms underlying chronic disease.
"Persistent CHIKV RNA can be detected in human and animal models but no one has been able to identify where the RNA resides due to insensitive techniques," said Deborah Lenschow.
"Using our reporter system we have demonstrated that cells can survive CHIKV infection, and these cells harbor most of the persistent RNA. Since many believe that this persistent RNA contributes to chronic arthritis, this system will be a useful tool to study the mechanisms underlying chronic disease," added Lenschow.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
